相似文献
1
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.哌柏西利在携带细胞周期蛋白依赖性激酶途径改变的进行性脑转移瘤中显示出颅内活性。
Nat Cancer. 2021 May;2(5):498-502. doi: 10.1038/s43018-021-00198-5. Epub 2021 Apr 8.
2
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).一项 CDK4/6 抑制剂帕博西尼在进展性脑肿瘤儿科患者中的 I 期临床试验：儿科脑瘤联盟研究（PBTC-042）。
Pediatr Blood Cancer. 2021 Apr;68(4):e28879. doi: 10.1002/pbc.28879. Epub 2021 Jan 6.
3
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.帕博西尼（PD0332991）-一种选择性且有效的细胞周期蛋白依赖性激酶抑制剂：药效学和临床开发综述。
JAMA Oncol. 2016 Feb;2(2):253-60. doi: 10.1001/jamaoncol.2015.4701.
4
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.哌柏西利联合来曲唑与来曲唑单药一线治疗雌激素受体阳性、HER2 阴性、晚期乳腺癌（PALOMA-1/TRIO-18）的随机 2 期研究。
Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.
5
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.CDK4/6抑制剂帕博西尼对DNA损伤修复的抑制作用可延缓照射后的颅内非典型畸胎样横纹肌样瘤和胶质母细胞瘤异种移植瘤的生长。
Neuro Oncol. 2016 Nov;18(11):1519-1528. doi: 10.1093/neuonc/now106. Epub 2016 Jul 1.
6
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.细胞周期蛋白依赖性激酶 4/6 抑制剂，哌柏西利和阿贝西利，在乳腺癌中的差异。
Jpn J Clin Oncol. 2019 Dec 18;49(11):993-998. doi: 10.1093/jjco/hyz151.
7
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.细胞周期蛋白依赖性激酶 4/6 抑制剂治疗激素受体阳性晚期乳腺癌的研究进展。
Ann Pharmacother. 2019 Feb;53(2):195-203. doi: 10.1177/1060028018793656. Epub 2018 Aug 6.
8
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.两种选择性CDK4和CDK6抑制剂在脑内的暴露情况以及CDK4和CDK6抑制与替莫唑胺联合应用于颅内胶质母细胞瘤异种移植模型中的抗肿瘤活性
Drug Metab Dispos. 2015 Sep;43(9):1360-71. doi: 10.1124/dmd.114.062745. Epub 2015 Jul 6.
9
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.含有视网膜母细胞瘤蛋白的生殖细胞肿瘤患者中细胞周期蛋白依赖性激酶 4/6 抑制剂帕博西利的 2 期临床试验。
Cancer. 2015 May 1;121(9):1463-8. doi: 10.1002/cncr.29213. Epub 2014 Dec 18.
10
Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.细胞周期蛋白依赖性激酶4/6抑制剂哌柏西利在癌症治疗中的研究进展
Anticancer Agents Med Chem. 2018;18(9):1241-1251. doi: 10.2174/1871521409666170412123500.
引用本文的文献
1
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.适应性队列设计与LAT1表达量表：QBS72S用于乳腺癌脑转移的2a期试验研究方案
BMC Cancer. 2025 Aug 15;25(1):1316. doi: 10.1186/s12885-025-14282-x.
2
Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors.小儿胶质瘤和神经纤维瘤病1型相关肿瘤的精准医学：小分子抑制剂的作用
Curr Oncol. 2025 May 15;32(5):280. doi: 10.3390/curroncol32050280.
3
Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A.在以KRAS-G12C和CDKN2A纯合缺失为特征的非小细胞肺癌脑转移模型中，阿达格拉西布与阿贝西利的联合治疗。
Acta Neuropathol Commun. 2025 May 2;13(1):88. doi: 10.1186/s40478-025-01993-2.
4
Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review.管腔型乳腺癌脑转移并昏迷的罕见表现：一例对阿贝西利有显著反应的病例报告及文献综述
Ther Adv Med Oncol. 2025 Mar 28;17:17588359251317847. doi: 10.1177/17588359251317847. eCollection 2025.
5
Cancer brain metastasis: molecular mechanisms and therapeutic strategies.癌症脑转移：分子机制与治疗策略
Mol Biomed. 2025 Feb 25;6(1):12. doi: 10.1186/s43556-025-00251-0.
6
Molecular evolution of central nervous system metastasis and therapeutic implications.中枢神经系统转移的分子进化及其治疗意义。
Trends Mol Med. 2025 Mar;31(3):240-251. doi: 10.1016/j.molmed.2024.09.008. Epub 2024 Oct 17.
7
Real-world outcomes in patients with brain metastases secondary to HR+/HER2- MBC treated with abemaciclib and local intracranial therapy.接受阿贝西利和局部颅内治疗的HR+/HER2-转移性乳腺癌继发脑转移患者的真实世界结局。
Oncologist. 2024 Oct 17. doi: 10.1093/oncolo/oyae274.
8
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition.星形胶质细胞诱导的 Cdk5 通过抑制 MHC-I 表达来逃避免疫识别，从而加速乳腺癌脑转移。
Nat Cell Biol. 2024 Oct;26(10):1773-1789. doi: 10.1038/s41556-024-01509-5. Epub 2024 Sep 20.
9
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.脑脊髓转移瘤：神经肿瘤学会和美国临床肿瘤学会关于临床管理和未来方向的共识综述。
Neuro Oncol. 2024 Oct 3;26(10):1781-1804. doi: 10.1093/neuonc/noae103.
10
Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases.帕博西尼与内分泌治疗联合用于激素受体阳性和人表皮生长因子受体 2 阴性的转移性乳腺癌，无论是否伴有脑转移。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338231206986. doi: 10.1177/15330338231206986.
本文引用的文献
1
Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma.人类脑转移瘤的基因组特征分析确定了转移性肺腺癌的驱动因素。
Nat Genet. 2020 Apr;52(4):371-377. doi: 10.1038/s41588-020-0592-7. Epub 2020 Mar 23.
2
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.CDK4/6 抑制剂治疗激素受体阳性、HER2 阴性、晚期或转移性乳腺癌患者：美国食品和药物管理局的汇总分析。
Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16.
3
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.帕博西尼联合西妥昔单抗治疗铂类耐药和西妥昔单抗耐药的人乳头瘤病毒阴性头颈部鳞癌：一项多中心、多队列、Ⅱ期临床试验。
Lancet Oncol. 2019 Sep;20(9):1295-1305. doi: 10.1016/S1470-2045(19)30405-X. Epub 2019 Jul 24.
4
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.纳武利尤单抗联合伊匹单抗治疗脑转移黑色素瘤。
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
5
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).奥希替尼治疗 T790M 阳性晚期非小细胞肺癌患者的中枢神经系统疗效：一项随机 III 期试验（AURA3）的数据。
J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.
6
Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.达拉非尼联合曲美替尼治疗BRAF突变型黑色素瘤脑转移患者（COMBI-MB）：一项多中心、多队列、开放标签的2期试验。
Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.
7
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂的奇闻：作用机制、耐药性及联合策略
Trends Cancer. 2017 Jan;3(1):39-55. doi: 10.1016/j.trecan.2016.11.006.
8
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.两项针对ALK阳性非小细胞肺癌经治患者的研究中，中枢神经系统对阿来替尼反应的汇总分析。
J Clin Oncol. 2016 Dec;34(34):4079-4085. doi: 10.1200/JCO.2016.68.4639. Epub 2016 Oct 31.
9
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.帕博利珠单抗用于治疗黑色素瘤或非小细胞肺癌且伴有未经治疗的脑转移患者：一项非随机、开放标签的2期试验的早期分析
Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.
10
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.帕博西尼治疗去分化或低分化脂肪肉瘤患者的无进展生存期：一项 2 期临床试验。
JAMA Oncol. 2016 Jul 1;2(7):937-40. doi: 10.1001/jamaoncol.2016.0264.
Zotero 插件